NR565/NR 565 ADVANCED PHARMACOLOGY MIDTERM
EXAM 2026/2027 | 2 Complete Versions with 350 Detailed
Verified Answers | Pass Guaranteed - A+ Graded
VERSION 1: Midterm Examination
SECTION A: Pharmacokinetics/Pharmacodynamics (Questions 1-25)
Q1: A 78-year-old patient with heart failure is prescribed digoxin 0.25 mg daily. The
prescriber notes the patient's creatinine clearance is 35 mL/min. Which
pharmacokinetic principle necessitates dose reduction in this patient?
A. Decreased hepatic first-pass metabolism due to aging
B. Reduced renal clearance leading to prolonged elimination half-life [CORRECT]
C. Increased volume of distribution secondary to decreased muscle mass
D. Enhanced gastrointestinal absorption due to reduced gastric acid secretion
Correct Answer: B
Rationale: Digoxin is primarily eliminated unchanged by the kidneys (approximately
60-80%). In patients with reduced renal function (CrCl <40 mL/min), the elimination
half-life of digoxin increases from the normal 36-48 hours to 3-5 days, leading to drug
accumulation and toxicity risk. The dose should be reduced to 0.125 mg daily or every
other day. Option A is incorrect because digoxin undergoes minimal hepatic
metabolism. Option C is partially true regarding aging changes but does not primarily
drive dose adjustment for digoxin. Option D is incorrect as digoxin absorption is not
significantly enhanced in renal impairment.
,Q2: A patient taking phenytoin for seizure control is prescribed fluconazole for
esophageal candidiasis. Which pharmacokinetic interaction is most concerning?
A. Fluconazole inhibits CYP2C9, increasing phenytoin levels [CORRECT]
B. Phenytoin induces fluconazole metabolism via CYP3A4
C. Fluconazole displaces phenytoin from albumin binding sites
D. Phenytoin inhibits fluconazole absorption in the GI tract
Correct Answer: A
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme responsible
for phenytoin metabolism. This inhibition can increase phenytoin levels by 50-75%,
leading to neurotoxicity (nystagmus, ataxia, confusion). Phenytoin has a narrow
therapeutic index (10-20 mcg/mL), making this interaction clinically significant. Option
B is incorrect because phenytoin does not significantly induce fluconazole metabolism.
Option C describes a valid mechanism but is less clinically significant than metabolic
inhibition. Option D is pharmacologically incorrect.
Q3: Which patient factor most significantly increases the volume of distribution (Vd) for
lipophilic drugs such as diazepam?
A. Chronic kidney disease
B. Obesity [CORRECT]
C. Cirrhosis with ascites
D. Congestive heart failure
Correct Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose tissue. In obesity, the
increased adipose mass creates a larger reservoir for drug distribution, significantly
increasing Vd. This prolongs elimination half-life (t½ = 0.693 × Vd/Cl) and may
necessitate loading dose adjustments. For diazepam specifically, the Vd increases from
,approximately 1 L/kg in normal-weight individuals to 2-3 L/kg in obesity. Option A
affects hydrophilic drugs more significantly. Option C may increase Vd for hydrophilic
drugs due to increased extracellular fluid. Option D typically reduces Vd due to
decreased tissue perfusion.
Q4: A 45-year-old patient with hepatic cirrhosis (Child-Pugh Class C) requires analgesia
following surgery. Which opioid requires the most significant dose reduction due to
altered pharmacokinetics?
A. Morphine
B. Oxycodone
C. Meperidine [CORRECT]
D. Hydromorphone
Correct Answer: C
Rationale: Meperidine is metabolized primarily by hepatic CYP enzymes to
normeperidine, a neurotoxic metabolite that accumulates in hepatic impairment and
can cause seizures. Additionally, meperidine itself accumulates due to reduced
clearance. The half-life of meperidine increases from 3-4 hours to 6-12 hours or longer
in severe liver disease. Normeperidine has a half-life of 15-30 hours and is renally
eliminated, creating a dangerous accumulation profile. While all opioids require caution
in liver disease, meperidine presents the highest risk profile and is generally
contraindicated in severe hepatic impairment.
Q5: Therapeutic drug monitoring of vancomycin is essential because:
A. It demonstrates zero-order elimination kinetics at therapeutic doses
B. There is a narrow therapeutic index with significant nephrotoxicity and ototoxicity risk
[CORRECT]
C. It undergoes extensive first-pass metabolism requiring trough level verification
, D. Protein binding varies significantly between patients, altering free drug
concentrations
Correct Answer: B
Rationale: Vancomycin exhibits a narrow therapeutic index with trough levels typically
targeted at 10-15 mcg/mL for most infections and 15-20 mcg/mL for serious infections
(pneumonia, meningitis, endocarditis). Levels >20 mcg/mL increase nephrotoxicity risk,
while inadequate levels promote resistance. Vancomycin follows first-order kinetics
(Option A is incorrect). It is administered IV and does not undergo first-pass metabolism
(Option C is incorrect). Vancomycin is approximately 55% protein bound with minimal
interpatient variability (Option D is incorrect).
Q6: Which pharmacodynamic principle explains why propranolol can precipitate
bronchospasm in patients with asthma?
A. Non-selective beta-blockade inhibits beta-2 mediated bronchodilation [CORRECT]
B. Alpha-1 blockade causes reflex bronchoconstriction
C. Muscarinic antagonism increases airway secretions
D. Histamine release from mast cells triggers bronchospasm
Correct Answer: A
Rationale: Propranolol is a non-selective beta-blocker that antagonizes both beta-1
(cardiac) and beta-2 (pulmonary) receptors. Beta-2 receptor activation normally
promotes bronchial smooth muscle relaxation (bronchodilation). Blockade of these
receptors in patients with reactive airway disease allows unopposed alpha-mediated
bronchoconstriction and cholinergic tone, precipitating bronchospasm. Cardioselective
beta-blockers (metoprolol, atenolol) are preferred in patients with asthma when
beta-blockade is necessary. Options B, C, and D describe mechanisms not associated
with propranolol's pharmacology.
EXAM 2026/2027 | 2 Complete Versions with 350 Detailed
Verified Answers | Pass Guaranteed - A+ Graded
VERSION 1: Midterm Examination
SECTION A: Pharmacokinetics/Pharmacodynamics (Questions 1-25)
Q1: A 78-year-old patient with heart failure is prescribed digoxin 0.25 mg daily. The
prescriber notes the patient's creatinine clearance is 35 mL/min. Which
pharmacokinetic principle necessitates dose reduction in this patient?
A. Decreased hepatic first-pass metabolism due to aging
B. Reduced renal clearance leading to prolonged elimination half-life [CORRECT]
C. Increased volume of distribution secondary to decreased muscle mass
D. Enhanced gastrointestinal absorption due to reduced gastric acid secretion
Correct Answer: B
Rationale: Digoxin is primarily eliminated unchanged by the kidneys (approximately
60-80%). In patients with reduced renal function (CrCl <40 mL/min), the elimination
half-life of digoxin increases from the normal 36-48 hours to 3-5 days, leading to drug
accumulation and toxicity risk. The dose should be reduced to 0.125 mg daily or every
other day. Option A is incorrect because digoxin undergoes minimal hepatic
metabolism. Option C is partially true regarding aging changes but does not primarily
drive dose adjustment for digoxin. Option D is incorrect as digoxin absorption is not
significantly enhanced in renal impairment.
,Q2: A patient taking phenytoin for seizure control is prescribed fluconazole for
esophageal candidiasis. Which pharmacokinetic interaction is most concerning?
A. Fluconazole inhibits CYP2C9, increasing phenytoin levels [CORRECT]
B. Phenytoin induces fluconazole metabolism via CYP3A4
C. Fluconazole displaces phenytoin from albumin binding sites
D. Phenytoin inhibits fluconazole absorption in the GI tract
Correct Answer: A
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme responsible
for phenytoin metabolism. This inhibition can increase phenytoin levels by 50-75%,
leading to neurotoxicity (nystagmus, ataxia, confusion). Phenytoin has a narrow
therapeutic index (10-20 mcg/mL), making this interaction clinically significant. Option
B is incorrect because phenytoin does not significantly induce fluconazole metabolism.
Option C describes a valid mechanism but is less clinically significant than metabolic
inhibition. Option D is pharmacologically incorrect.
Q3: Which patient factor most significantly increases the volume of distribution (Vd) for
lipophilic drugs such as diazepam?
A. Chronic kidney disease
B. Obesity [CORRECT]
C. Cirrhosis with ascites
D. Congestive heart failure
Correct Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose tissue. In obesity, the
increased adipose mass creates a larger reservoir for drug distribution, significantly
increasing Vd. This prolongs elimination half-life (t½ = 0.693 × Vd/Cl) and may
necessitate loading dose adjustments. For diazepam specifically, the Vd increases from
,approximately 1 L/kg in normal-weight individuals to 2-3 L/kg in obesity. Option A
affects hydrophilic drugs more significantly. Option C may increase Vd for hydrophilic
drugs due to increased extracellular fluid. Option D typically reduces Vd due to
decreased tissue perfusion.
Q4: A 45-year-old patient with hepatic cirrhosis (Child-Pugh Class C) requires analgesia
following surgery. Which opioid requires the most significant dose reduction due to
altered pharmacokinetics?
A. Morphine
B. Oxycodone
C. Meperidine [CORRECT]
D. Hydromorphone
Correct Answer: C
Rationale: Meperidine is metabolized primarily by hepatic CYP enzymes to
normeperidine, a neurotoxic metabolite that accumulates in hepatic impairment and
can cause seizures. Additionally, meperidine itself accumulates due to reduced
clearance. The half-life of meperidine increases from 3-4 hours to 6-12 hours or longer
in severe liver disease. Normeperidine has a half-life of 15-30 hours and is renally
eliminated, creating a dangerous accumulation profile. While all opioids require caution
in liver disease, meperidine presents the highest risk profile and is generally
contraindicated in severe hepatic impairment.
Q5: Therapeutic drug monitoring of vancomycin is essential because:
A. It demonstrates zero-order elimination kinetics at therapeutic doses
B. There is a narrow therapeutic index with significant nephrotoxicity and ototoxicity risk
[CORRECT]
C. It undergoes extensive first-pass metabolism requiring trough level verification
, D. Protein binding varies significantly between patients, altering free drug
concentrations
Correct Answer: B
Rationale: Vancomycin exhibits a narrow therapeutic index with trough levels typically
targeted at 10-15 mcg/mL for most infections and 15-20 mcg/mL for serious infections
(pneumonia, meningitis, endocarditis). Levels >20 mcg/mL increase nephrotoxicity risk,
while inadequate levels promote resistance. Vancomycin follows first-order kinetics
(Option A is incorrect). It is administered IV and does not undergo first-pass metabolism
(Option C is incorrect). Vancomycin is approximately 55% protein bound with minimal
interpatient variability (Option D is incorrect).
Q6: Which pharmacodynamic principle explains why propranolol can precipitate
bronchospasm in patients with asthma?
A. Non-selective beta-blockade inhibits beta-2 mediated bronchodilation [CORRECT]
B. Alpha-1 blockade causes reflex bronchoconstriction
C. Muscarinic antagonism increases airway secretions
D. Histamine release from mast cells triggers bronchospasm
Correct Answer: A
Rationale: Propranolol is a non-selective beta-blocker that antagonizes both beta-1
(cardiac) and beta-2 (pulmonary) receptors. Beta-2 receptor activation normally
promotes bronchial smooth muscle relaxation (bronchodilation). Blockade of these
receptors in patients with reactive airway disease allows unopposed alpha-mediated
bronchoconstriction and cholinergic tone, precipitating bronchospasm. Cardioselective
beta-blockers (metoprolol, atenolol) are preferred in patients with asthma when
beta-blockade is necessary. Options B, C, and D describe mechanisms not associated
with propranolol's pharmacology.
